EUVIMEDEUVIMED entdecken
Open Access

Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study

Hannah R Rosenblum iD, Jan M Griffin, Masatoshi Minamisawa, Narayana Prasad, John Vest, Matthew T White, Scott D Solomon, Daniel Burkhoff, Mathew S Maurer

European Journal of Heart Failure · 2023

DOI: 10.1002/ejhf.2783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Hannah R Rosenblum und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center-NYP Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Heart Failure, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, New York Academy of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transthyretin-mediated (ATTR) amyloidosis is caused by deposition of transthyretin protein fibrils in the heart, nerves, and other organs. Patisiran, an RNA interference therapeutic that inhibits hepatic synthesis of transthyretin, was approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy based on the phase 3 APOLLO study. We use left ventricular (LV) stroke volume (SV) to quantify LV function overtime and non-invasive pressure–volume techniques to delineate the effects of patisiran on LV mechanics in the pre-specified cardiac subpopulation of the APOLLO study. Methods and results Left ventricular SV was assessed by transthoracic echocardiography at baseline, and after 9 and 18 months of therapy. To determine the mechanisms underlying changes in LV SV, non-invasive pressure–volume parameters, including the end-systolic and end-diastolic pressure–volume relationship, were derived using single beat techniques. At baseline, the mean SV was 51 ± 14 ml. At 9 months, the least-squares mean change in SV was −0.3 ± 1.2 ml for patisiran and −5.4 ± 1.9 ml for placebo (p = 0.021). At 18 months, the least-squares mean change in SV was −1.7 ± 1.3 ml for patisiran and − 8.1 ± 2.3 ml for placebo (p = 0.016). Decline in LV SV was driven by diminished LV capacitance in placebo relative to patisiran.

Conclusions

Patisiran may delay progression of LV chamber dysfunction starting at 9 months of therapy. These data elucidate the mechanisms by which transthyretin-reducing therapies modulate progression of cardiac disease and need to be confirmed in ongoing phase 3 trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAmyloid Neuropathies, FamilialHumansStroke VolumePrealbuminRNA, Small Interfering

Stichwörter der Autor:innen

ATTR amyloidosisHaemodynamicsHeart failureRNAi therapeuticsTransthyretin amyloidosis

Substanzen

PrealbuminpatisiranRNA, Small Interfering

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center-NYP Hospital, New York, NY, USA.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • Cardiovascular Research Foundation, New York, NY, USA.

ORCID-Profile: Hannah R Rosenblum

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • New York Academy of Medicine
  • NHLBI Division of Intramural Research

Zitieren

APA

Rosenblum, H. R., Griffin, J. M., Minamisawa, M., Prasad, N., Vest, J., White, M. T., Solomon, S. D., Burkhoff, D., & Maurer, M. S. (2023). Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2783

Vancouver

Rosenblum HR, Griffin JM, Minamisawa M, Prasad N, Vest J, White MT, et al. Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2783

BibTeX
@article{Rosenblum2023,
  author = {Rosenblum, Hannah R and Griffin, Jan M and Minamisawa, Masatoshi and Prasad, Narayana and Vest, John and White, Matthew T and Solomon, Scott D and Burkhoff, Daniel and Maurer, Mathew S},
  title = {Effect of Patisiran on Stroke Volume in Hereditary Transthyretin-Mediated Amyloidosis: Insights from Pressure–Volume Analysis of the APOLLO Study},
  journal = {European Journal of Heart Failure},
  year = {2023},
  doi = {10.1002/ejhf.2783}
}
Kostenlos starten →